PellePharm pellepharm.com


Public list: BIO 2016 (619) Pharma Startups (4733)

PellePharm is developing topical patidegib, a first-in-class topical hedgehog inhibitor, to decrease the number of surgically-eligible basal cell carcinomas in Gorlin Syndrome patients.

PellePharm is developing topical patidegib, a first-in-class topical hedgehog inhibitor, to decrease the number of surgically-eligible basal cell carcinomas in Gorlin Syndrome patients.

Company (Alive / Active)

Phone: 510-502-6144

Fax:

101 Mission Street
Suite 2050
San Francisco, 94105
California, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
PellePharm $31.8M Jul 3, 2018

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related PellePharm Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
Undisclosed InvestorsOtherSeries C, Unattributed - III, Series B, Unattributed - II, Series A - II, Series A, Unattributed
BridgeBio PharmaCorporationPalo Alto, California, United StatesSeries B - III, Series B - II
See all 2 investors
There is no Board of Directors data available for this company. Please select another tab.
There is no Competitors data available for this company. Please select another tab.

Patents

Title Application Date Patent Date Status
(Patent / Application)
Method for relief of and treatment of pruritus Feb 09, 2017 Application
Topical formulations for delivery of hedgehog inhibitor compounds and use thereof Jun 03, 2016 Application